Cannabinoids are found in the marijuana plant (cannabis sativa) and are said to be effective in pain management from pain symptoms such as multiple sclerosis, diabetic neuropathy, peripheral neuropathy and nausea and vomiting. A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain.
The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non-psychotic effect. Cannabinoids may have the ability to activate a novel neuroprotective mechanism to save the brain from deterioration. This paper will review this statement and give a conclusion to its liability.
Here is the full scientific article if you wish to download it.
Although CB1 receptor triggering evokes neuroprotection in reaction to cannabinoids, some cannabinoids have been said to be peroxisome proliferator triggered receptor (PPAR) ligands, giving a different securing action. Researchers in this study looked into the properties of a number of cannabinoids to trigger PPARα and for N-oleoylethanolamine (OEA), an endogenous cannabinoid-like chemical (ECL), to bring about neuroprotection. Mixtures of PPARα habitation and gene transactivation possibility were taken out in cell-free and transfected HeLa cell solutions respectively.
In vivo estimates of PPARα triggering by way of fat motility and gene transcription was taken out in mice. Neurosecurity in vivo was studied in wild-type and PPARα gene-disrupted mice. Overall, it was seen that the potential for a range of cannabinoid chemicals, of diverse structures, to trigger PPARα and indicate that at least some of the neurosecure abilities of these drugs could be controlled by nuclear receptor triggering.
Overall, the results laid out here give strong evidence that specific cannabinoids (WIN 55212-2, OEA, noladin ether and virodhamine) are PPARα agonists, and indicate a novel means by which the numerous impacts of cannabinoids, in both the central nervous system and periphery, could be pushed towards the light. In addition to its well-recognized role in lipid metabolism, PPARα triggering showed obvious advantageous impacts in ischemic neuronal injury, which is likely to be in cahoots with its anti-inflammatory method via the NF–κB pathway. These findings not only widen the possible application of cannabinoids as analgesic drugs but also lends a hand to PPARα as a new citation for neurosecurity treatment.